Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer
Latest Information Update: 17 Jan 2025
At a glance
- Drugs Cabozantinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Therapeutic Use
Most Recent Events
- 14 Jan 2025 Status changed from active, no longer recruiting to completed.
- 21 Jan 2024 Planned End Date changed from 1 Jul 2033 to 19 Dec 2024.
- 21 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 19 Dec 2024.